NorthStrive Biosciences, a wholly-owned subsidiary of PMGC Holdings Inc., has filed two new U.S. patent applications to expand its EL-22 and EL-32 intellectual property portfolio into potential human pharmaceutical applications. The filings aim to preserve lean muscle mass in human patients experiencing muscle loss from GLP-1 and obesity-related weight loss treatments. The applications have been assigned U.S. Patent Application Nos. 19/709,895 for EL-22 and 19/709,950 for EL-32.

The new patent applications represent a strategic expansion from the company's previous focus on animal health and agricultural applications into potential human-use applications. The filings are directed toward preserving lean muscle mass in patients suffering from sarcopenia, obesity-related weight loss treatment, malnutrition, neurogenic atrophy, or physical inactivity. Both applications specifically address obesity-related weight loss treatments, including GLP-1 receptor agonists, as well as dual and triple agonist therapies targeting GLP-1, GIP, and/or glucagon pathways.

Patent Application Details

New Human-Use Patent Claims

The newly filed applications include claims directed to the potential use of EL-22 and EL-32 to preserve lean muscle mass in patients undergoing obesity-related weight loss treatment. The claims cover various pharmaceutical product approaches and delivery methods.

• Human-use applications for preserving lean muscle mass in patients experiencing muscle loss from sarcopenia, obesity-related weight loss treatment, malnutrition, neurogenic atrophy, or physical inactivity.
• Use in patients undergoing obesity-related weight loss treatment, including GLP-1 receptor agonists, dual agonists targeting GLP-1, GIP, and/or glucagon pathways, and triple agonists targeting GLP-1, GIP, and glucagon pathways.
• EL-22 pharmaceutical product approaches involving isolated Myo-2 peptide, Myo-2 peptide multimers, and fusion proteins involving myostatin mature protein fused to Myo-2 peptide or Myo-2 peptide multimers.
• EL-32 pharmaceutical product approaches involving a microorganism transformed with a cell surface display vector linked to genes encoding myostatin and activin A proteins.
• EL-32 microorganism embodiments involving lactic acid bacteria, including Lactobacillus paracasei.
• Combination and co-administration approaches, including taking EL-22 or EL-32 together with apelin or ursolic acid, compounds associated with muscle support.
• Multiple pharmaceutically acceptable delivery forms, including oral, injectable, nasal, topical, and other delivery formats.

Expansion of the EL-22 and EL-32 IP Portfolio

The EL-22 application includes claims directed to pharmaceutical product approaches involving myostatin-derived Myo-2 peptide constructs for potential use in preserving lean muscle mass in humans. The filing includes claims directed to an isolated Myo-2 peptide, Myo-2 peptide multimers, a fusion protein of myostatin mature protein fused to a Myo-2 peptide, and a fusion protein of myostatin mature protein fused to a Myo-2 peptide multimer.

The EL-32 application includes claims directed to pharmaceutical product approaches involving a microorganism transformed with a cell surface display vector operably linked to genes encoding myostatin and activin A proteins. The filing includes claims directed to potential use of the microorganism to preserve lean muscle mass in a human patient, including embodiments involving lactic acid bacteria such as Lactobacillus paracasei.

Targeting a Major Emerging Need in the GLP-1 Market

The company believes the rapid adoption of GLP-1 and related incretin-based obesity treatments, such as semaglutide and tirzepatide, may create an emerging opportunity for complementary approaches focused on preserving lean muscle mass during weight loss. While GLP-1 and next-generation obesity therapies have become widely recognized for their role in weight management, the company believes maintaining lean muscle mass during obesity-related weight loss may become an increasingly important area of product development and clinical focus.

PMGC Holdings Inc. is positioning its precision manufacturing platform to capitalize on the growing demand within the space exploration sector. The company's wholly owned subsidiaries—A&B Aerospace, SVM Machining, and AGA Precision Systems—provide advanced manufacturing capabilities aligned with the quality and compliance standards required by aerospace, defense, and space customers. PMGC aims to leverage these assets to serve supply chains for satellites, launch systems, and space infrastructure.

Exposure to High-Growth Space Economy Segments

PMGC's platform is aligned with several high-growth areas of the space economy, including satellites, launch vehicles, spacecraft, and lunar infrastructure. According to The Space Foundation, the global space economy reached a record $613 billion in 2024, up 7.8% year-over-year. McKinsey and the World Economic Forum have projected the sector could grow to approximately $1.8 trillion by 2035. These figures represent total industry size and are not projections of the company's financial performance.

U.S.-Based Precision Manufacturing Capabilities

The company's U.S.-based operating companies provide tight-tolerance CNC machining, fabrication, and complex component manufacturing. PMGC's manufacturing platform is positioned to support three key areas of the space economy:

Established Customer Relationships and Growth Opportunity

PMGC's operating companies have established a track record of serving customers across the space, aerospace, and defense sectors, including SpaceX, Moog, and Lawrence Berkeley National Laboratory. According to historical sales data, work performed for space-related programs and applications represented approximately 5.7% of total top-line revenue across A&B Aerospace, SVM Machining, and AGA Precision Systems over the past two years. PMGC management believes this represents an established base of space-sector revenue to grow from, noting that these capabilities were never actively marketed to the broader space economy under prior ownership.